Direxion Daily Financial Bull 3X Shares ETF
FAS
iShares US Home Construction ETF
ITB
SPDR S&P Homebuilders ETF
XHB
4
Spdr S&P Insurance Etf
KIE
5
Direxion Daily Energy Bear 2X Shares
ERY
CN Stock MarketDetailed Quotes
Hybio Pharmaceutical (300199)
- 19.77
- -2.22-10.10%
Market Closed Jun 26 15:00 CST
17.46BMarket Cap184.77P/E (TTM)
22.20High19.74Low462.25KlotVolume21.86Open21.99Prev Close949.40MTurnover6.20%Turnover Ratio482.20P/E (Static)883.24MShares31.1952wk High23.54P/B14.73BFloat Cap15.8852wk Low26.39Limit Up745.17MShs Float52.44Historical High17.59Limit Down11.19%Range %2.39Historical Low--Dividend TTM20.54Avg Price262.42KlotAsk--Div Yield TTM100Lot Size175.40KlotBid
300199 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
300199 Orderflow
Unit: --
300199 Orderflow Trend
IntradayDayWeekMonth
No Data
Hybio Pharmaceutical (300199) News
Hanyu Pharma (300199.SZ) announced that its subsidiary has received approval for the marketing application of linaclotide active pharmaceutical ingredient.
Hanyu Pharma (300199.SZ) announced that on June 21, 2026, its wholly owned subsidiary, Hanyu Pharma (Wuhan) Co., Ltd., received a "Notice of Approval for Marketing Authorization Application of Chemical Active Pharmaceutical Ingredients" issued by the National Medical Products Administration.
Hybio Pharmaceutical Secures Indonesian Marketing Nod for Postpartum Hemorrhage Drug
Hansoh Pharma (300199.SZ): The Phase III clinical trials for both weight loss and blood sugar reduction indications of semaglutide injection in China have achieved equivalence standards.
Hansoh Pharmaceutical (300199.SZ) announced recently that its Semaglutide injection has obtained Phase III clinical trial data. The data shows that the Phase III clinical trials for both weight loss and blood sugar reduction indications in the domestic market have achieved equivalence standards.
Shareholders Can Be Confident That Hybio Pharmaceutical's (SZSE:300199) Earnings Are High Quality
Hanyu Pharmaceutical: Summary of the 2025 Annual Report
Hanyu Pharmaceutical: 2025 Annual Report
Hybio Pharmaceutical (300199) Stock Forum
Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28% 1
The company's balance sheet is not considered strong due to its high debt and liabilities, coupled with a decrease in revenue and a loss before interest and tax. The company is considered risky due to these factors.
1
Despite Hybio Pharmaceutical's recent poor growth, its high P/S ratio indicates investor optimism for a business turnaround. However, with medium-term revenue decline and expected industry growth of 35%, these prices may not be sustainable. Shareholders may face a tough period unless circumstances improve.
The company's high P/S ratio and decreasing revenues do not match, causing concerns for investors. Unless the recent medium-term conditions improve significantly, investors may find it difficult to perceive the share price as fair value.
Hybio Pharmaceutical's falling revenue and pre-tax losses pose concerns over its debt level, implying potential threat to the company while its shares seem unaffected. It's deemed risky due to these factors.
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)